These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31304637)

  • 1. Long-Term Safety and Efficacy of JR-131, a Biosimilar of Darbepoetin Alfa, in Japanese Patients With Renal Anemia Undergoing Hemodialysis: Phase 3 Prospective Study.
    Nishi S; Yamada M; Tsuruya K; Masakane I; Nakamoto H
    Ther Apher Dial; 2020 Apr; 24(2):136-145. PubMed ID: 31304637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JR-131, a Biosimilar of Darbepoetin Alfa, for the Treatment of Hemodialysis Patients With Renal Anemia: A Randomized, Double-Blinded, Parallel-Group Phase 3 Study.
    Nishi S; Yamada M; Tsuruya K; Masakane I; Nakamoto H
    Ther Apher Dial; 2020 Apr; 24(2):126-135. PubMed ID: 31325212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
    Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
    Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
    J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
    Akizawa T; Macdougall IC; Berns JS; Bernhardt T; Staedtler G; Taguchi M; Iekushi K; Krueger T
    Am J Nephrol; 2019; 49(4):271-280. PubMed ID: 30852574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.
    Warady BA; Barcia J; Benador N; Jankauskiene A; Olson K; Podracka L; Shavkin A; Srivaths P; Wong CJ; Petersen J
    Pediatr Nephrol; 2018 Jan; 33(1):125-137. PubMed ID: 28815341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of darbepoetin alfa for anemia in children with chronic kidney disease: a multicenter prospective study in Japan.
    Hattori M; Uemura O; Hataya H; Ito S; Hisano M; Ohta T; Fujinaga S; Kise T; Gotoh Y; Matsunaga A; Ito N; Akizawa T;
    Clin Exp Nephrol; 2014 Aug; 18(4):634-41. PubMed ID: 24013765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan.
    Tanaka T; Nangaku M; Imai E; Tsubakihara Y; Kamai M; Wada M; Asada S; Akizawa T
    Clin Exp Nephrol; 2019 Feb; 23(2):231-243. PubMed ID: 30182223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study.
    Kim Y; Park SK; Cho WY; Joo KW; Shin SK; Kim DJ; Kim YL; Son SH; Chung W; Lee KY; Park SK; Kim JK; Kim SW; Kang DH; Kim JK; Jeon JS; Lee KW; Lee CH; Oh DJ; An WS; Lee JS; Kang GW; Do JY; Lee JP; Jin K
    BioDrugs; 2020 Feb; 34(1):99-110. PubMed ID: 31749113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
    J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study.
    Nangaku M; Kondo K; Ueta K; Kokado Y; Kaneko G; Matsuda H; Kawaguchi Y; Komatsu Y
    Nephrol Dial Transplant; 2021 Aug; 36(9):1731-1741. PubMed ID: 33650630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial.
    Sinha SD; Bandi VK; Bheemareddy BR; Thakur P; Chary S; Mehta K; Pinnamareddy VR; Pandey R; Sreepada S; Durugkar S
    BMC Nephrol; 2019 Mar; 20(1):90. PubMed ID: 30866856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
    Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S
    JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.
    Hayashi T; Maruyama S; Nangaku M; Narita I; Hirakata H; Tanabe K; Morita S; Tsubakihara Y; Imai E; Akizawa T;
    Clin J Am Soc Nephrol; 2020 May; 15(5):608-615. PubMed ID: 32245781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa.
    Tani J; Ito Y; Tatemichi S; Yamakami M; Fukui T; Hatano Y; Kakimoto S; Kotani A; Sugimura A; Mihara K; Yamamoto R; Tanaka N; Minami K; Takahashi K; Hirato T
    PLoS One; 2020; 15(4):e0231830. PubMed ID: 32302352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis.
    Thadhani R; Guilatco R; Hymes J; Maddux FW; Ahuja A
    Am J Nephrol; 2018; 48(3):214-224. PubMed ID: 30196301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
    Eckardt KU; Agarwal R; Aswad A; Awad A; Block GA; Bacci MR; Farag YMK; Fishbane S; Hubert H; Jardine A; Khawaja Z; Koury MJ; Maroni BJ; Matsushita K; McCullough PA; Lewis EF; Luo W; Parfrey PS; Pergola P; Sarnak MJ; Spinowitz B; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Zwiech R; Chertow GM
    N Engl J Med; 2021 Apr; 384(17):1601-1612. PubMed ID: 33913638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
    Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
    Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of CKD-11101 (darbepoetin-alfa proposed biosimilar) compared with NESP in anaemic chronic kidney disease patients not on dialysis.
    Lee JH; Ha Chung B; Joo KW; Shin SK; Kim YL; Na KY; Do JY; Park SK; Shin BC; Lee JS; Kim YW; Kim SW; Lee KW; Kang GW; An WS; Shin GT; Han S; Yang CW
    Curr Med Res Opin; 2019 Jun; 35(6):1111-1118. PubMed ID: 30569763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.